Why is ERIS Lifescience falling/rising?

As of 24-Sep, ERIS Lifesciences Ltd is experiencing a decline in its stock price, currently at 1,627.25, reflecting a decrease of 5.8 points or 0.36%. The stock has been losing value for the past two days, with a total drop of 0.93% during this period. Additionally, the stock's performance over the last week shows a decline of 1.09%, and over the past month, it has fallen by 8.17%. Despite these recent downturns, the company has demonstrated strong financial health, evidenced by a high return on capital employed (ROCE) of 17.80% and a low debt-to-EBITDA ratio of 1.15 times. Furthermore, it has shown consistent returns over the last three years, outperforming the BSE500 index, which may provide some support for its valuation amidst the current price drop.
In the broader market context, the Sensex has also seen a slight decline of 1.18% over the past week, indicating that the market sentiment is somewhat negative. However, ERIS Lifesciences' year-to-date performance remains strong, with an increase of 18.87%, significantly outperforming the Sensex's 4.58% gain. The stock's recent price movement may be influenced by falling investor participation, as indicated by an 84.34% drop in delivery volume compared to the five-day average, which could signal reduced interest among investors. Despite the current decline, the high institutional holdings at 26.57% suggest that more informed investors are backing the company, which may provide a buffer against further declines.